Objectives: PPP is a chronic, debilitating, painful inflammatory skin disease characterized by localized, sterile pustules on the palms of the hands and soles of the feet. By understanding the burden of disease in this population, targeted interventions that improve patient quality of life can be developed. To our knowledge, this study is the first of its kind to describe HCRU in patients with PPP. Methods: Patients were identified as having PPP if they had $1 inpatient or 2 outpatient ICD-10 L40.3 diagnosis codes, separated by 30 to 365 days. All analyses were conducted via the Aetion Evidence Platform TM v3.17, using Optum® Clinformatics TM Data Mart, a US administrative claims database. The study period was from October 1, 2015 to March 31, 2019, with the first diagnosis code marking the index date. A general population matched cohort (MC) of 4:1, based on age and sex, was generated for context. No formal comparisons were conducted. Patient characteristics, treatment, and all-cause HCRU calculated for each visit type (inpatient, outpatient, and emergency department [ED]) during the 12-month follow up (FU) were analyzed. Results: 1291 patients with PPP were identified at baseline, and 708 had $12 months' FU. Compared with the MC, patients with PPP were more likely to have a diagnosis of hyperlipidemia (PPP: 28.7% vs MC: 20.0%), anxiety (PPP: 7.6% vs MC: 5.5%), and depression (PPP: 7.0% vs MC: 5.1%) at baseline. During the 12-month FU, 391 patients with PPP (55.2%) were treated with a systemic therapy (biologic or non-biologic) and had a median of 18.5 outpatient visits, 23.6% of patients had ED visits (median: 1.0), and 10% had inpatient visits (median: 1.0). Conclusions: Patients with PPP have more comorbidities than those in the MC, as well as high HCRU, highlighting an unmet need among these patients.

S77ObjectiveS: Characterize baseline clinical and patient-centric characteristics of type 2 diabetes mellitus (T2DM) patients who met criteria for an online patient engagement tool. MethOdS: This study analyzed pooled baseline data from T2DM patients identified for a prospective evaluation of an online patient engagement tool at two sites; Henry Ford Health System and Northwell Health. Patients were eligible if they were ≥ 18 years of age, diagnosed with T2DM, and had a baseline Patient Activation Measure (PAM) level 2 'Becoming Aware' or 3 'Taking Action'. Clinical assessments and patient reported outcomes (PROs) were collected online and described using summary statistics. ReSultS: 662 participants consented and provided PAM data, with 15.9% and 48.8% at PAM levels 2 and 3, respectively. Patients at levels 1 (5.4%) and 4 (29.9%) were ineligible. 363 patients met all eligibility criteria for this analysis. Participants were primarily white (58.4%), females (59.0%) with a mean age of 57.4 (SD: 11.1) years and PAM level of 3 (76.6%). Mean time since diagnosis of T2DM was 10.4 (SD: 8.3) years. The most common comorbidities were hypertension and hypercholesterolemia/hyperlipidemia (20.7% each). 39.4% of patients had hemoglobin A1c ≥ 8.0% (mean: 8.0%, SD: 1.8) and mean body mass index (BMI) was 36.3 (SD: 7.4) kg/m2, with 80.2% being considered obese (BMI ≥ 30 kg/m2). Mean physical and mental component summary scores from the Short Form 12 were 40.9 (SD: 16.1) and 44.9 (SD: 17.1), respectively, indicating impaired functioning in each dimension. Mean Diabetes Distress Scale scores indicated moderate regimen-related distress (3.1, SD: 1.2) and emotional burden (2.7, SD: 1.2), suggesting clinical attention is necessary. cOncluSiOnS: Clinical measurements and PROs in our population of T2DM patients with PAM level 2/3 suggest a need for clinical and lifestyle intervention. Further research is needed to confirm appropriate clinical intervention and the potential effectiveness of targeted patient engagement tools.

No abstract